• Lundbeck Jumps as Depression Drug Gets Praise: Copenhagen Mover
  • Roche Experimental Leukemia Drug Helps Shrink Tumors
  • Algeta Surges to Record After Prostate Cancer Drug Approval
  • AstraZeneca Advances Three Cancer Drugs Into Late-Stage Trials
  • SAC Owes $549 Million for Elan Trades, Investors Say
  • AmEx, Merck Lead $16.5 Billion of Company Bond Issuance in U.S.
  • Chesapeake Partners Holdings in 1st Quarter: 13F Alert
  • Tudor Sells Stakes Apple, Emerging Markets Exchange Fund
  • Google’s Page Describes Speech Malady, Funds Research
  • J&J Wins Expanded Approval of Simponi for Bowel Disease
  • Bristol-Myers Targets Heart-Failure Drugs in R&D Effort
  • Merck Plans $6.5 Billion Bond Offering for Stock Repurchases
  • Bayer, Algeta Win U.S. Approval for Prostate Cancer Drug
  • Actavis Gaining More From Purchase Than Sale: Real M&A
  • Fraud Settlement at Ranbaxy Set to Spur Exports: Corporate India
« Previous 1 2 3 4 5 Next »